NCT06013423View on ClinicalTrials.gov

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

October 31, 2031

Study Completion Date

October 31, 2032

Conditions
Acute Leukemia of Ambiguous LineageAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmHematopoietic and Lymphatic System NeoplasmMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaChronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspirate

Undergo bone marrow aspirate

DRUG

Cyclophosphamide

Receive IV

DRUG

Cyclosporine

Receive IV or PO

PROCEDURE

Diagnostic Imaging

Undergo diagnostic imaging

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Fludarabine Phosphate

Receive IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Mycophenolate Mofetil

Receive IV

OTHER

Survey Administration

Ancillary studies

DRUG

Thiotepa

Receive IV

RADIATION

Total-Body Irradiation

Undergo high-dose or middle-intensity TBI

PROCEDURE

Umbilical Cord Blood Transplantation

Undergo UCBT

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cord Blood Network

UNKNOWN

lead

Fred Hutchinson Cancer Center

OTHER